TKM Ebola

Drug Profile

TKM Ebola

Alternative Names: Ebola SNALP; siEbola-2; siRNA Ebola virus infection therapeutic - Arbutus Biopharma; TKM-100201; TKM-100802; TKM-Ebola; TKM-Ebola Kikwit

Latest Information Update: 29 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protiva Biotherapeutics
  • Developer Arbutus Biopharma
  • Class Antivirals; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Ebola virus infections

Highest Development Phases

  • Suspended Ebola virus infections

Most Recent Events

  • 24 Oct 2016 Phase-I development suspended for Ebola virus infections in USA (Arbutus BioPharma pipeline; October 2016)
  • 12 Oct 2016 TKM Ebola is available for licensing as of 12 Oct 2016. http://arbutusbio.com/partners/partnering-licensing-opportunities.php
  • 08 Aug 2016 Arbutus receives patent issuance for Lipid nanoparticle (LNP) delivery technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top